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Background: Brain-derived neurotrophic factor (BDNF) plays a role in synaptic plasticity
and neuroprotection. BDNF has well-established pro-survival effects, whereas its
precursor protein, proBDNF, induces apoptosis. Thus, it has been suggested that the
proBDNF/BDNF ratio could be an indicator of neuronal health. Access to neurons is,
understandably, limited. Because of their similarities, platelets have been put forward as a
non-invasive biomarker of neuronal health; indeed, they store large quantities of BDNF
and can release it into circulation upon activation, similarly to neurons. However, whether
platelets also express the precursor proBDNF protein remains unknown. We therefore
sought to characterize proBDNF levels in human platelets and plasma.
Methods: The presence of proBDNF was assessed by immunoblotting, cell fractionation,
flow cytometry, and confocal microscopy in washed platelets from 10 healthy volunteers.
Platelets from 20 independent healthy volunteers were activated with several classical
agonists and the release of BDNF and proBDNF into plasma was quantified by ELISA.
Results: Platelets expressed detectable levels of proBDNF (21 ± 13 fmol/250 x 106
platelets). ProBDNF expression was mainly localized in the intracellular compartment. The
proBDNF to BDNF molar ratio was ~1:5 in platelets and 10:1 in plasma. In stark contrast
to the release of BDNF during platelet activation, intraplatelet and plasma concentrations
of proBDNF remained stable following stimulation with classical platelet agonists,
consistent with non-granular expression.
Conclusions: Platelets express both the mature and the precursor form of BDNF.
Whether the intraplatelet proBDNF to BDNF ratio could be used as a non-invasive
biomarker of cognitive health warrants further investigation.
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The brain-derived neurotrophic factor (BDNF) is a member of
the neurotrophin family initially identified in the central nervous
system where it is known to play a role in synaptic plasticity,
long-term memory, cognition and neuroprotection (1–3). It is
produced as a precursor protein, proBDNF, which is then
cleaved by intracellular or extracellular proteases to release the
pro-domain and the mature BDNF protein (2, 4). Like BDNF,
proBDNF can be released by neurons following an action
potential (5, 6), and has an active biological function, which is
in opposition with the pro-survival functions of BDNF. Indeed,
proBDNF induces neuronal apoptosis (5), reduces dendritic
arborization (6), and negatively regulates synaptic plasticity (6,
7) and transmission (6).
The contrast between the role of BDNF and that of its
precursor has led to the hypothesis that the regulation of the
proBDNF/BDNF ratio is important for maintenance of a healthy
nervous system (4, 5, 7, 8). In line with this hypothesis, it has
been shown that the regulation of proBDNF cleavage is a key
process in long-term hippocampal synaptic plasticity (9) and in
memory (10, 11). Furthermore, some authors suggest that
impairment in proBDNF cleavage could be important in the
pathophysiology of cognitive disorders (12, 13). Several studies
report a change of the proBDNF/BDNF ratio in neurons or
cerebrospinal fluid in diverse neurocognitive disorders such as
Alzheimer’s disease (13, 14), major depressive disorder (8),
autism (15), and affective disorders (4).
Although it was at first discovered in the brain, we now know
that BDNF is also present in blood, where it is essentially stored
in platelets (16, 17). BDNF levels in platelets can reach 100- to
1,000-fold those of neurons, making platelets the most important
peripheral reservoir of BDNF (17–20). Similarly to neurons,
platelets store BDNF mainly in a-granules (21) and release it
into the bloodstream during platelet activation (16). While
proBDNF has also been reported in circulation (22, 23), the
origin of peripheral proBDNF is unknown. It is particularly
puzzling, as the presence of proBDNF in platelets has never
been confirmed.
We therefore sought to investigate the presence of proBDNF
in platelets; to compare the plasma vs. platelet levels of proBDNF
in healthy volunteers; and to investigate the release profiles of
proBDNF vs. BDNF in response to platelet activation induced by
different agonists. As several studies have suggested that platelets
could be a potential biomarker of neuropsychiatric disorders,Abbreviations: AA, arachidonic acid; ACD, acid citrate dextrose; ADP, adenosine
diphosphate; BDNF, brain-derived neurotrophic factor; BSA, bovine serum
albumin; Ctrl, control; DABCO, 1,4-diazabicyclo(2,2,2)octane; EDTA,
ethylenediaminetetraacetic acid; ELISA, enzyme-linked immunosorbent assay; IB,
immunoblotting; IQR interquartile range; kDa, kilodaltons; PBMC, peripheral blood
mononuclear cell; PBS, phosphate buffered saline; PFA, paraformaldehyde; PPP,
platelet-poor plasma; proBDNF, pro-brain-derived neurotrophic factor; PRP,
platelet-rich plasma; RIPA buffer, radioimmunoprecipitation assay buffer;
rProBDNF, recombinant pro-brain-derived neurotrophic factor; RT, room
temperature; SD, standard deviation; SDS, sodium dodecyl sulfate; SDS-PAGE,
sodium dodecyl sulfate polyacrylamide gel electrophoresis; TBS-T, tris buffered
saline-tween; TRAP, thrombin-related activating peptide; Tris, tris
(hydroxymethyl)aminomethane.
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intraplatelet proBDNF/BDNF ratio as a biomarker of
neurocognitive health (24–28).MATERIALS AND METHODS
Participant Selection
This study was approved by the Montreal Heart Institute
Scientific and Research Ethics Committee (REC reference:
#2016-1996) and all participants gave written informed
consent. A total of 30 participants were included in this study;
in 10 subjects, platelets were isolated and washed to better
characterize the presence of proBDNF in platelets, and in 20
subjects, proBDNF and BDNF levels were quantified in platelets
and plasma following platelet activation. Participants were
exempt of chronic diseases, did not require chronic medical
treatment, had refrained from drugs influencing platelet function
in the 2 weeks preceding blood sample collection, and had
normal platelet count and hemoglobin levels. Participants with
a history of bleeding were excluded.
Blood Collection and Platelet Isolation
Using a 21G needle, blood was drawn by venipuncture into 30 ml
syringes containing either acid citrate dextrose (ACD-A) in a 1:5
volume ratio for experiments carried out in washed platelets, or
sodium citrate 3.2% in 1:9 volume ratio for experiments in
platelet-rich plasma (PRP). Blood samples were gently mixed
by inversion, transferred to 50 ml tubes and centrifuged at 200 g
for 15 min without a brake to prepare PRP and at 1,000 g for 10
min to prepare platelet-poor plasma (PPP).
Native citrated PRP was used without adjustment of platelet
count for platelet aggregation experiments, with autologous PPP
used to set baselines.
To obtain washed platelets, prostaglandin E1 (1 µM) was added
to ACD-anticoagulated PRP prior to centrifugation at 1,000 g for
10 min. Platelets were resuspended in Tyrode’s buffer (137 mM
NaCl, 11.9 mM NaHCO3, 0.4 mM NaH2PO4, 2.7 mM KCl,
1.1 mM MgCl2, 5.6 mM glucose, pH 7.4). This washing
procedure was repeated three times. Platelets were counted
using a Beckman Coulter hematology analyzer (Ac-T 5diff AL)
and adjusted to a final concentration of 2.5 x 108/ml for flow
cytometry experiments or 2 x 109/ml for cell fractionation and
deglycosylation experiments. Platelets were allowed to rest at room
temperature (RT) for 60 min prior to functional experiments.
Cell Fractionation
Washed platelets (2 x 109/ml) resuspended in phosphate buffered
saline (PBS) were lysed by three freeze-thaw cycles (temperatures
of −80 and 37°C). The samples were then centrifuged at
200,000 g for 90 min at 4°C. The supernatant representing the
cytosolic fraction was transferred to a new tube, while the pellet
representing the cytoskeleton and membranes was solubilized in
radioimmunoprecipitation assay (RIPA) buffer [150 mM NaCl,
5 mM EDTA pH 8.0, 50 mM Tris-HCl pH 8.0, 1% NP40, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS)]November 2020 | Volume 11 | Article 575607
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solubilized sample was then centrifuged at 100,000 g for 30 min
at 4°C. The supernatant in which the membranes were dissolved
was transferred to a new tube, while the pellet representing the
cytoskeleton was resuspended in 1X Laemmli buffer and heated
at 95°C for 5 min with vigorous vortexing. Samples were then
assessed by immunoblotting using antibodies against proBDNF
(as described below), BDNF (Biosensis, M-1744, monoclonal
mouse antibody, 1 mg/ml), p-selectin (Santa Cruz, sc-6941
polyclonal goat antibody, 0.26 mg/ml), a-tubulin (Sigma-
Aldrich, T5168 monoclonal mouse antibody, clone B-5-1-2,
1.225 mg/ml), and p65 NF-ĸB (Santa Cruz, sc-372 polyclonal
rabbit antibody, 0.4 mg/ml). The equivalent in the protein
content of 3 x 107 platelets was loaded for each fraction on
the gel.
Deglycosylation
Washed platelets and U87-MG cells were lysed with ice-cold
RIPA buffer for 20 min. Platelet or U87-MG cell lysates (100 mg)
were denatured at 100°C for 10 min in a glycoprotein
denaturating buffer (0.5% SDS, 40 mM DTT, B1704S, New
England Biolabs, MA, USA) and allowed to cool to RT.
GlycoBuffer 2 with 1% NP-40 (New England Biolabs, MA,
USA) was added to denatured proteins, and PNGase F
(P0704S, New England Biolabs, MA, USA) was then added to
a final concentration of 50 units per µg of total protein. The
mixture was incubated at 37°C for 1 h, frozen and kept at −80°C.
Immunoblotting was performed using antibodies against
proBDNF (Biosensis, R-176, polyclonal rabbit antibody, 0.25
mg/ml), CD42b (Santa Cruz, sc-59051, monoclonal mouse
antibody, clone PM6/40, 1 mg/ml), or sortilin/NT3 (Abcam,
ab16640, polyclonal rabbit antibody, 2 mg/ml). The equivalent
of the lysate of 3 x 107 platelets was loaded in each well.
ProBDNF and a2-Macroglobulin
Immunoblotting
Human recombinant proBDNF (Alomone Labs, Israel) and
Human Brain Cerebral Cortex Whole Tissue Lysate (Novus
Biologicals, Bio-Techne, Oakville, ON, Canada) were used as
positive controls. Native platelet whole cell lysates were incubated
in Laemmli loading buffer (250 mM Tris pH 6.8, 8% SDS, 40%
glycerol, 20% b-mercaptoethanol, and 0.02% bromophenol blue)
before heating at 95°C for 5min. Protein samples were separated on
a 12% SDS-polyacrylamide gel electrophoresis (PAGE), transferred
onto aPVDF0.2 µmmembrane andfixedwith glutaraldehyde 0.5%
for 30min.Membranes were washed three timeswithTBS-T (Tris-
buffered saline, 0.1%Tween20) for 10minandblocked for 1hatRT
in blocking solution [3% bovine serum albumin (BSA) in TBS-T or
5%milk inTBS-T]before incubationwithantiproBDNForantia2-
macroglobulin antibodies (Biosensis, anti-proBDNF R-176
polyclonal rabbit antibody, 0.25 mg/ml; R&D systems, anti-
proBDNF mab31751 monoclonal mouse antibody, clone 584412,
0.5mg/ml;Abbexa, anti-a2-macroglobulin abx132389,monoclonal
mouse antibody, 1 mg/ml) overnight at 4°C. The blots were then
washed and incubated with HRP-conjugated goat anti-rabbit or
goat anti-mouse secondary antibody (Jackson ImmunoResearchFrontiers in Immunology | www.frontiersin.org 3Laboratories, diluted 1:10,000 in 5%milk) for 1 h at RT. Luminata
Classico Western HRP Substrate (Millipore) was used for
chemiluminescent detection.
Flow Cytometry
Washed platelets (2.5 x 108/ml), U87-MG or U251-MG cells
were fixed with 1% paraformaldehyde (PFA) for 20 min at RT, a
fraction of which was also permeabilized using 0.1% Triton-X for
15 min at RT. Platelets and neuroblastic cells were then
incubated at RT with mouse anti-human proBDNF antibody
(R&D System, mab31751, monoclonal mouse antibody, clone
584412, diluted 1:25 or Biosensis, R-176 polyclonal rabbit
antibody diluted 1:25) or mouse IgG2b/rabbit isotype control
(R&D System, MAB004 and AB-105-C diluted 1:25) for 30 min.
Alexa Fluor 488 or 647 conjugated donkey anti-mouse or rabbit
secondary antibody (Invitrogen, diluted 1:100) was added for 30
min at RT in the dark. Samples were analyzed using the
MACSQuant Analyzer 10 (Miltenyi Biotec, Germany).
Confocal Microscopy
Glass coverslips were pre-coated with 0.1% poly-L-lysine for 15
min at RT. Platelets fixed with 1% PFA for 20 min at RT were
transferred onto pre-coated coverslips and allowed to adhere
overnight at 4°C. Fixed U251-MG cells were plated on the pre-
coated coverslips and incubated overnight at 37°C/5% CO2
incubator. Platelets and U251-MG cells were permeabilized
using 0.1% Triton X-100 in PBS for 10 min at RT. Coverslips
were then washed twice with PBS and blocked with 3% donkey
serum in PBS for 30 min at RT. Coverslips were then washed two
times with PBS and proBDNF labelling was performed using an
anti-proBDNF primary antibody (R&D, mab31751, monoclonal
mouse antibody, clone 584412, 5 µg) for 2 h at RT followed by
two PBS washes and an incubation with an Alexa Fluor 488-
conjugated donkey anti-mouse secondary antibody (1:200) for
90 min at RT. Mouse IgG2b was used as isotype control antibody
(R&D System, MAB004, clone 20116, 5 µg). After two more
washes, U251-MG coverslips were incubated with diluted DAPI
(10 mg/ml, 1:1,000) for 5 min and washed again twice with PBS.
Coverslips were then treated with 1,4-diazabicyclo(2,2,2)octane
(DABCO) mounting medium (25 mg/ml DABCO in 90%
glycerol/10% PBS solution) overnight in the dark. Fluorescence
was visualized using a Zeiss LSM510 confocal microscope.
Light Transmission Aggregometry
Platelet aggregation was measured using a Chronolog
Aggregometer (Model 700, Havertown, PA, USA) at 37°C with
continuous stirring at 1,200 rpm. Platelet aggregation traces were
recorded for 6 min using the AGGRO/LINK®8 Software
package. The following agonists were used: adenosine
diphosphate (ADP, Sigma Aldrich) 10 mM, arachidonic acid
(AA, Cayman Chemical) 1 mM, collagen (Chronolog) 5 mg/ml,
or thrombin-related activating peptide (TRAP-amide, Bachem)
3 mM. A vehicle-treated PRP sample was used under stirring
conditions as a control. Ethylenediaminetetraacetic acid (EDTA,
5 mM) was added at the end of the incubation to stop platelet
activation and agitation was continued for 1 min. Platelets and
plasma were separated by centrifugation at 1,000 g for 5 min andNovember 2020 | Volume 11 | Article 575607
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with lysis buffer (1% NP40, 20 mM Tris pH 8.0, 137 mM NaCl,
10% glycerol, 2 mM EDTA, 1 mM sodium orthovanadate)
containing Pierce Protease and Phosphatase Inhibitor Mini
Tablets (Thermo Scientific). Lysed platelets and supernatants
containing the platelet releasate were kept frozen at −80oC
until analysis.
Assessment of BDNF and proBDNF Levels
Plasma and intraplatelet concentrations of BDNF and proBDNF
were determined by ELISA (R&D System, DY248 and DY3175).
Plasma and platelet lysate samples were centrifuged at 3,000 rpm
for 5 min to remove cellular debris. Samples were diluted 1:15 in
reagent diluent (Supplementary Figures 1 and 2). Assays were
performed in accordance with manufacturer’s instructions.
Cross-reactivity for mature BDNF was negligible (1.4%) in the
proBDNF assay, and low (13%) for proBDNF in the BDNF assay.
Each condition was tested in duplicate. Colorimetric reading was
performed with the Infinite F50 plate reader (Tecan, Männedorf,
Switzerland) at 450 nm, with a reference at 620 nm.
Statistical Analyses
Continuous variables are presented as mean and standard
deviation (SD) or median and interquartile range (IQR) when
distribution deviated from normal. N refers to the number of
independent experiments with each experiment representing a
different biological sample. Repeated-measures analysis of
variance (ANOVA) with Geisser-Greenhouse correction for
sphericity and Dunnett’s correction for multiple comparisons
was performed to assess differences between agonist-stimulated
conditions. Pearson correlation was used to explore the
association between proBDNF and BDNF levels. All analyses
were carried out with GraphPad Prism Software version 8 for
MacOS (GraphPad Software, San Diego, CA, USA). A
multiplicity-adjusted p value < 0.05 was considered significant.RESULTS
Human Platelets Contain proBDNF
To assess the presence of proBDNF in platelets, we performed
immunoblotting experiments on washed platelets using two
different proBDNF antibodies (Supplementary Figure 3). To
verify that detection of proBDNF in platelets was not due to
plasma protein contamination, we cross-checked for
immunoreactivity for a2-macroglobulin in platelet lysates
(Figure 1F), showing absence of this plasma protein in the
washed platelet preparation. Human cortex used as positive
control, expressed proBDNF at ~32–35 kDa (Figure 1A).
Recombinant proBDNF produced in Escherichia coli was
detected at a lower molecular weight (~25–27 kDa). In platelets,
we detected a band at ~32–35 kDa (Figure 1A). Following
incubation with PNGase F, a clear shift was seen for CD42b, a
platelet membrane glycoprotein used as a positive control for N-
deglycosylation (Figure 1C). Although a lower band did appear
below the 32–35 kDa band for proBDNF, the same band was alsoFrontiers in Immunology | www.frontiersin.org 4visible in the absence of platelet protein, likely due to non-specific
binding to PNGase F (expected molecular weight 36 kDa).
Treatment of U87-MG human glioblastoma cell lysates with
PNGase F also failed to show N-deglycosylation of proBDNF.
This suggests that the differences in molecular weight between
platelet and neuronal BDNF vs. recombinant proBDNF were not
attributable to N-glycosylation.
Platelet proBDNF Is Localized
in the Cytoplasm
The cytosolic, membrane (including granular membranes), and
cytoskeletal fractions of platelets were obtained by differential
ultracentrifugation and analyzed by immunoblotting. To
confirm the cellular compartmentation of the fractions, we
used NF-kB as a marker for the cytosolic fraction, P-selectin
for the membrane fraction, and a-tubulin for the cytoskeletal
fraction (Figure 1B). Mature BDNF was mainly found in the
membrane fraction (presumably in a-granules), but also at lower
levels in the cytosolic and cytoskeletal fractions (Figure 1B). In
contrast, proBDNF was distributed similarly in each of the three
fractions (Figure 1B). Interestingly, a lower band around the 15-
kDa marker which could correspond to the cleaved pro-domain
of proBDNF (29, 30), exclusively segregated into the cytoplasmic
fraction (Figure 1B).
Immunoblotting for a-tubulin showed immunoreactivity in
the membrane and cytosol fractions, suggesting suboptimal
cytoskeletal fraction separation. Therefore, to further investigate
proBDNF localization, we performed flow cytometry and confocal
microscopy on fixed and permeabilized platelets. A mean of
13 ± 8% of platelets expressed proBDNF at their surface, and
40± 20%were positive for proBDNFonce cellswere permeabilized
(Figure 1D). To validate that detection of proBDNFwas not due to
plasma protein adsorption on platelet plasma membranes, acid-
washed platelets were compared with platelets washed in Tyrode’s
buffer at physiological pH, with no significant drop in proBDNF
signal in acid-washed platelets (Supplementary Figure 4).
Confocal microscopy imaging also suggested that proBDNF was
present at themembrane and in the cytosol of platelets (Figure1E).
HumanglioblastomaU87-MGandU251-MGcells usedaspositive
controls showedmainly intracellular expressionbyflowcytometry,
and microscopy further confirmed that expression was essentially
cytosolic and nuclear (Figures 1D, E).
Human Platelets Contain Less proBDNF
Than BDNF
To assess the relative abundance of proBDNF and BDNF in
platelets, we quantified both proteins by ELISA in 20 healthy
volunteers (Table 1). The levels of proBDNF were variable from
one individual to the other (Figure 2A), but under basal
conditions, proBDNF levels were significantly lower than BDNF
levels (proBDNF 1,085 ± 672 pg/250 x 106 platelets equivalent to
21±13 fmol/250x106 platelets compared to4,516±2,915pg/250 x
106 platelets equivalent to 167 ± 108 fmol/250 x 106 platelets for
BDNF). The mean intraplatelet proBDNF/BDNF molar ratio was
0.18 ± 0.14 (Figure 2B), meaning that there was ~1 molecule of
proBDNF for ~5 molecules of BDNF in platelets (Table 2).November 2020 | Volume 11 | Article 575607





FIGURE 1 | Human platelets contain proBDNF. (A) ProBDNF immunoblotting of human washed platelet lysates (15 µg) from six different healthy volunteers.
Recombinant proBDNF (3 ng) and human cortex lysate (3 µg) were used as positive controls. Molecular weight is indicated on the left (kDa) and primary antibody on
the right. Experiments representative of n=9 for R-176 and n=10 for mab31751 antibody. IB, immunoblotting. (B) Immunoblotting of proBDNF and BDNF in different
fractions of washed human platelets. P-Selectin was used as control protein in the membrane fraction, p65 NF-ĸB was used as control protein in the cytosol, and a-
tubulin was used as control protein in the cytoskeleton. The equivalent of the protein content of 3 x 107 platelets was loaded for each fraction on the gel.
Representative experiment of n=4 different volunteers. (C) ProBDNF treatment with PNGase F in washed human platelet lysates. U87-MG glioblastoma cells were
used as a control. rProBDNF, recombinant proBDNF (3 ng); cortex, human cortex lysate (3 µg); platelets, whole human platelet lysate (representative experiment of
n=4 different volunteers, 7.5 x 108 platelets per well); −PNGF, platelets treated with GlycoBuffer, and incubated at 37°C for 60 min without PNGase F; +PNGF,
platelets treated with GlycoBuffer and incubated at 37°C for 60 min with PNGase F; PNGF alone, PNGase F incubated at 37°C for 60 min without platelet lysate.
CD42b and sortilin were used as controls of protein deglycosylation in platelets and in U87-MG cells, respectively. n=3 different volunteers for PNGase treatments in
human platelets and n=4 independent experiments for U87-MG cells. (D) Representative flow cytometry experiment showing surface and intracellular proBDNF in
human washed platelets and in U87-MG and U251-MG glioblastoma cell lines. Mouse IgG2b was used as isotype control. Percentage of expression are indicated on
the figure. n=10 different healthy volunteers for human platelets; n=3 independent experiments for each glioblastoma cell line. (E) Confocal microscopy imaging of
proBDNF in human permeabilized washed platelets (top) and in permeabilized U-251 MG cells (bottom). Mouse IgG2b was used as isotype control. ProBDNF was
labelled using Alexa488 fluorochrome (in green). Nuclei were stained with DAPI (in blue). Scale bar = 2 µm and 200 µm for washed platelets and U-251 MG cells
images, respectively. (F) Immunoblotting of a2-macroglobulin at increasing quantities of loaded proteins (1–20 µg) obtained from a washed platelet lysate or platelet-
poor plasma (PPP) from the same individual (#23). a-tubulin was used as loading control. Molecular weight is indicated on the left (kDa) and primary antibody on the
right. PPP, platelet poor plasma; PLTs, platelets; IB, immunoblotting.Frontiers in Immunology | www.frontiersin.org November 2020 | Volume 11 | Article 5756075
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Are Higher Than Those of BDNF
We then investigated whether a similar proBDNF/BDNF ratio
was found in circulation. Under basal conditions, we found the
opposite pattern in plasma to that observed in platelets (Figure
2C), i.e., concentrations of proBDNF in plasma were much
higher than those of BDNF (proBDNF 28,019 ± 19,695 pg/ml
or 541 ± 380 fmol/ml compared with BDNF 2,064 ± 1,825 pg/ml
or 76 ± 68 fmol/ml). We calculated the mean proBDNF/BDNF
ratio to be ~10 molecules of proBDNF for ~1 molecule of BDNF
in plasma (Figure 2D, Table 2).
BDNF and proBDNF Concentrations Are
Correlated in Platelets But Not in Plasma
Figures 2E, F show the association between intraplatelet and
plasma levels of proBDNF and BDNF. While a linear correlation
was seen between BDNF and proBDNF in platelets (r=0.71;
p=0.0005, Figure 2E), no such association was seen in plasma
(r=0.14; p=0.58, Figure 2F), suggesting the regulation of proBDNF/
BDNF ratio is different in the cellular and plasma compartments.
Unlike BDNF, proBDNF Is Not Released
During Platelet Activation
We next studied whether platelets have the ability to release
proBDNF in the same manner they release BDNF during their
activation. Platelet responses to four different platelet agonists
(ADP, TRAP, AA, and collagen) were assessed in platelet-richFrontiers in Immunology | www.frontiersin.org 6plasma from 20 healthy volunteers. As expected, intraplatelet
concentrations of BDNF decreased with the addition of platelet
agonists and plasma concentrations increased, confirming that
BDNF was released from platelets during their activation
(Figures 3A, B). As shown in Figure 3C, resting platelets
contained ~70% of total BDNF present in PRP, and this
proportion decreased to ~20% after platelet activation.
In contrast, intracellular and plasma levels of proBDNF
remained stable in response to platelet activation (Figures 3D, E).
Only ~10% of proBDNF in PRP appeared to be stored in platelets,
regardless of platelet activation status (Figure 3F). As a
consequence, platelet activation significantly changed the
proBDNF to BDNF ratio in plasma from 10:1 to close to 2:1
(Table 2).DISCUSSION
In the present study, we have shown that: 1) platelets contain
proBDNF in a 1:5 ratio to BDNF; 2) the levels of intraplatelet
proBDNF correlate strongly with those of BDNF, whereas no such
association was seen in plasma; 3) the pool of intraplatelet proBDNF
represents approx. 10% of total circulating proBDNF, whereas
approx. 70% of circulating BDNF is stored in platelets; and 4)
platelet activation does not lead to proBDNF secretion, in contrast
to BDNF that is largely released following platelet activation.
Presence of proBDNF in Platelets
Since the early 1990’s, numerous reports have conclusively
shown platelets to contain large quantities of BDNF as to
represent the major peripheral reservoir of this neurotrophin
(16, 17, 31, 32). Circulating proBDNF, on the other hand, has
received considerably less attention. While it is known that
proBDNF is produced by many cell types including neurons
(5, 6), megakaryocytes (18), lymphocytes (33), skeletal muscle
(34), and endothelial cells (35), the contribution of these cells to
circulating proBDNF levels is not elucidated.
To our knowledge, there is only one group that has
investigated the presence of proBDNF in platelets (18).
Chacón-Fernández et al. have shown platelet precursor cells,
megakaryocytes, to express proBDNF, but failed to detect
proBDNF in mouse, rat, and human platelets with an antibody
targeting the mature BDNF protein (18). With the use of
antibodies targeting the prodomain of proBDNF, we were able
to show that platelets do contain proBDNF, albeit in a much
lesser proportion to its mature counterpart. The origin of BDNF
in platelets remains debated. Chacón-Fernández et al. have
shown BDNF to be present in megakaryocytes, their
proplatelet extensions, and in platelets, suggesting BDNF is
inherited from megakaryocytes (18). Fujimura et al. have
shown platelets to internalize exogenous BDNF, suggesting
they may acquire it from the bloodstream (16). The relative
contribution of inherited vs. internalized BDNF in platelets
remains unknown.
Our results show a high variability in circulating BDNF and
proBDNF levels among healthy individuals. While theTABLE 1 | Characteristics of the healthy volunteers included in the ELISA
quantification study (n = 20).
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FIGURE 2 | Molar concentrations of proBDNF are lower in platelets and higher in plasma than those of BDNF. ELISA quantification of proBDNF and BDNF levels in
the intraplatelet (A, B) and plasma (C, D) compartments. Concentrations are normalized for 250 x 106 platelets. Horizontal bar represents median, *p<0.05. (E, F)
Correlation between BDNF and proBDNF molar concentrations in human platelets (E) and in plasma (F). Dotted lines represent 95% confidence intervals, n=20
participants (#1 to #20).TABLE 2 | proBDNF/BDNF ratio as a function of platelet activation status.
Platelet state Mean proBDNF/BDNF ratio (n=20) SD 95% CI p-value
Intraplatelet Basal 0.18 0.14 0.12–0.24
Activated
ADP (10 mM) 0.46 0.33 0.31–0.60 0.0003
TRAP (3 mM) 0.56 0.43 0.37–0.75 0.0003
AA (1 mM) 0.60 0.37 0.43–0.76 0.00001
Collagen (5 mg/ml) 0.59 0.43 0.40–0.78 0.0002
Plasma Basal 10.2 7.9 6.7–13.7
Activated
ADP (10 mM) 2.5 4.3 0.60–4.4 0.0001
TRAP (3 mM) 2.3 3.6 0.70–3.8 0.00005
AA (1 mM) 3.6 7.4 0.38–6.8 0.003
Collagen (5 mg/ml) 2.4 3.1 1.02–3.8 0.0002Frontiers in Immunology | www.frontiersin.org 7 November 2020 | Volume 11 | Article 575607
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been the object of investigation, several factors are known to
affect blood levels of mature BDNF, including age (36–39), sex
(37–39), smoking status (37), and body mass index or weight (38,
39). Our small sample size precludes multivariate analyses to
explore the contribution of these characteristics to circulating
levels of proBDNF/BDNF in this study, but this should be
explored in larger cohorts. Attention should also be given to
ethnicity, as it appears to be an important determinant of
circulating proBDNF levels (40).
Notwithstanding, for the 20 individuals tested, we found
significantly less proBDNF than BDNF in platelets, resulting in
a mean 1:5 ratio of proBDNF to BDNF. This ratio is in line with
levels observed in the central nervous system, where the
proBDNF/BDNF ratio was 1:10 in hippocampal cells (29, 41).
However, while proBDNF was shown to be N-glycosylated in
human neurons (42) and saliva (43), the platelet proBDNF did
not appear to be sensitive to PNGase F treatment, thus arguing
against N-glycosylation in these cells. It should be noted however
that PNGase treatment of U87-MG glioblastoma cells also failed
to induce changes in molecular weight, suggesting that other
post-translational modifications may explain the differences of
molecular weight with recombinant proBDNF produced in
bacteria (25–27 kDa). Five different isoforms of proBDNF have
been repertoried in the literature, each with a different molecular
weight (44–46). Whether differences in molecular weight seen in
this study are due to different isoforms expressed or different
post-translational modifications of proBDNF in megakaryocytes
and platelets requires further investigation.Frontiers in Immunology | www.frontiersin.org 8In stark contrast to intraplatelet levels, plasma levels of
proBDNF were 10 times those of BDNF. This is surprising, in
view of the short half-life of BDNF in circulation (47, 48)
suggesting that proBDNF is protected from degradation in
plasma. It has been shown that mature neurotrophins
including BDNF bind reversibly to a2-macroglobulin (49), a
plasma protease inhibitor and transporter, protecting them
against proteolytic degradation and clearance pathways (50).
Whether proBDNF can similarly bind to a2-macroglobulin
and thus be protected from proteolytic cleavage, or uses a
different mechanism to avoid degradation, is worthy
of investigation.
Not All Platelets Express proBDNF
Our flow cytometry experiments showed that a mean of 13 ± 8% of
platelets had proBDNF on their surface and 40 ± 20% were
proBDNF-positive upon permeabilization. Although platelets
underwent gentle washing procedures to avoid platelet activation,
we can not eliminate the possibility that some of the proBDNF
found on the platelet surface is in fact residual from plasma.
However, no plasma protein contamination was detected in our
platelet lysates (Figure 1F), and acid washing to remove plasma
proteins adsorbed on cell membranes did not reduce the proBDNF
signal in platelets (Supplementary Figure 2), thus limiting this
possibility. We observed a high level of correlation between
intracellular BDNF and proBDNF levels, and found a proBDNF
fragment of approx. 15-kDa consistent with the proBDNF pro-
domain in the platelet cytosol, both suggesting that an intracellular
regulation mechanism of the proBDNF/BDNF ratio is present inA B
D E F
C
FIGURE 3 | Unlike BDNF, intraplatelet proBDNF is not released during platelet activation. Intraplatelet (A, D) and plasma (B, E) concentrations of BDNF and
proBDNF following platelet activation by different agonists. Intraplatelet concentrations are normalized for 250 x 106 platelets. Proportion of BDNF (C) and proBDNF
(F) in plasma vs. in platelets are expressed in percentage. Error bar represents IQR, *p < 0.05 vs. ctrl, n=20 participants (#1 to #20). Ctrl, control; ADP, adenosine
diphosphate; TRAP, thrombin receptor-activating peptide; AA, arachidonic acid.November 2020 | Volume 11 | Article 575607
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and inherited by platelets during thrombopoiesis. In neurons,
proBDNF cleavage is processed by furin, metalloproteinases
(MMP-9) (51, 52), and protein convertases (PC1, PC5, PACE4,
and PC7) (4). Platelets express several proteases that could possibly
participate in BDNF maturation, such as furin-like proprotein
convertases (53) and other proteases stored in platelets granules
such as MMP-2 and MMP-9 (54). Thus, it is conceivable that
proBDNF cleavage occurs in platelets in a regulated manner. While
the body of evidence on the role of the pro-domain in the nervous
system is growing, it was undetected for many years (55), and its
characterization required a complex optimization of techniques
(29). In the peripheral nervous system, the cleaved pro-domain is
10-fold more abundant than proBDNF, and both the pro-domain
and BDNF are secreted from the same synaptic intracellular vesicles
(29). The pro-domain appears to contribute to regulation of
neuronal growth, and to essential mechanisms of depression and
psychological disorders (30, 56, 57). Therefore, a thorough
investigation of the presence and the potential role of the pro-
domain in platelets is warranted.
Unlike BDNF, proBNDF Is Not Released
Upon Platelet Activation
Our results confirm that platelets release approximately 50% of
their BDNF content during activation. Tamura et al. have made the
same observation and found that there are two distinct pools of
BDNF in human platelets: a releasable pool of BDNF stored in a-
granules and a non-releasable pool of BDNF localized in the platelet
cytoplasm (21). However, Tamura et al. used an antibody raised
against the mature portion of BDNF, and therefore could not
distinguish between the precursor and mature proteins. In our
experiments using antibodies raised against the proBDNF pro-
domain, we have found a significant proportion of proBDNF to be
present in the cytoplasm, as well as in the membrane and
cytoskeletal fractions, which might explain the absence of release
upon platelet activation. Considering that intraplatelet proBDNF
represents only approximately 10% of total circulating proBDNF,
and that platelets do not release significant levels of proBDNF upon
activation, it is unlikely that plasma proBDNF comes from platelets.
Several groups have explored the possibility that plasma
proBDNF is neuronal in origin. However, while it has been
suggested by some authors that mature BDNF might cross the
blood-brain barrier in mice and rats (58, 59), this finding was not
supported by others (47, 48), and none have specifically investigated
the permeability of the blood-brain barrier to proBDNF. Thus, the
origin of the high levels of proBDNF seen in plasma remains to be
elucidated. Notwithstanding, platelet activation induces a dramatic
change in the plasma proBDNF to BDNF ratio, by releasing large
quantities of mature BDNF (Table 2). Any future use of plasma
proBDNF to BDNF ratio as a potential biomarker for
neurocognitive health will thus need to take into account platelet
activation status.
Limitations
Although we were able to show proBDNF in human platelets by
three different techniques, there are limitations that require pause.Frontiers in Immunology | www.frontiersin.org 9First, the platelet release experiments were performed in plasma,
which naturally contains BDNF and proBDNF. Thus, it is possible
that the experimental model does not allow the detection of a weak
release of proBDNF. Second, we have added EDTA at the end of
the platelet activation experiments to inhibit calcium-dependent
proteases. We cannot exclude the possibility that proBDNF was
rapidly cleaved into BDNF following platelet activation and thus
might not be measurable in the supernatant. However,
intraplatelet proBDNF levels remained unchanged during
platelet activation, which lends credence to the fact that there is
no detectable proBDNF release upon platelet activation and argues
against the two previous limitations. Our cell fractionation
experiments suggest that proBDNF is equally present in
cytoplasmic, membrane and cytoskeletal fractions. We used a
crude technique for separation of cell fractions, with good
resolution of the cytoplasmic from the membrane fraction, but
with residual contamination from the cytoskeletal fraction. These
results should therefore be interpreted alongside flow cytometry
and microscopy assessments. Finally, it is possible that proBDNF
and BDNF bind to plasma proteins, which might mask epitopes
from detection by ELISA. However, both stimulated and control
samples were handled in the same way, and the rise of BDNF
levels was readily detectable in plasma. Thus, it is unlikely that
release of proBDNF was missed in agonist-stimulated vs.
resting platelets.CONCLUSIONS
To our knowledge, this study is the first to report the presence of
proBDNF in human platelets. Granted we do not provide the
certainty of sequencing through mass spectrometry, but within the
limitations of our assays, we are confident that what we are seeing
is indeed proBDNF in platelets. It seems however unlikely
that platelets contribute to a significant extent to circulating
proBDNF levels, since only ~10% of the total circulating levels
of proBDNF were found within platelets. Furthermore, in contrast
to BDNF, platelets did not release proBDNF during activation,
reinforcing the likelihood that the high levels of proBDNF
observed in plasma originate from another cell type. The
correlation between BDNF and proBDNF concentrations within
platelets leads us to hypothesize that there is an intracellular
mechanism regulating the proBDNF/BDNF ratio, albeit it could
be vestigial from megakaryocytes. Further studies are required to
elucidate the role of proBDNF in platelet function and the
contribution of the intraplatelet proBDNF/BDNF ratio as a
determinant of platelet biology. How the platelet proBDNF/
BDNF ratio relates to neuronal levels, and whether platelets
could be used as non-invasive biomarkers of neuronal health,
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Contraction Regulates BDNF/TrkB Signaling to Modulate Synaptic Function
through Presynaptic cPKCa and cPKCbI. Front Mol Neurosci (2017) 10:147.
doi: 10.3389/fnmol.2017.00147
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